Company news

Racura Oncology Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Collaboration to Understand Zantrene Cardioprotection

March 2, 2023

Race Receives Cardioprotection Ethics Trial Approval

January 31, 2023

Race supports Study of Extramedullary AML

December 22, 2022

Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO

December 15, 2022

Race Appoints Damian Clarke-Bruce as CEO & Managing Director

December 13, 2022

Positive Pre-IND Guidance from FDA on Zantrene

November 22, 2022

Response to ASX Price Query

October 18, 2022

Race Develops Improved IV Formulation of Zantrene

September 27, 2022

Race Initiates New Drug Discovery Program

September 26, 2022

Race Oncology: Update - Notification of buy-back - RAC

July 27, 2022

Race Oncology: RAC Quarterly Investor Presentation

July 27, 2022

Race Oncology: Quarterly Activity Report & Appendix 4C

July 21, 2022

Zantrene Protects Mouse Hearts from Chemotherapy Damage

June 29, 2022

Zantrene shows synergy with kinase inhibitors in melanoma

June 27, 2022

Zantrene Improves Immune Therapy Treatment of Melanoma

June 21, 2022

Race Oncology Announces On-Market Share Buyback

June 8, 2022

EMD AML MDS Trial Expands to Europe

June 7, 2022

Zantrene AML trial in Israel advances to Phase 2

May 27, 2022

Race Receives Governance Approval for AML EMD & MDS Trial

May 11, 2022

Race receives Human Ethics AML Trial Approval

April 6, 2022

Supply Agreement for EMD AML Trial

March 30, 2022

Zantrene highly effective in EMD AML Mouse Model

March 16, 2022

Race Oncology: ASX Small and Mid-Cap Conference Presentation

March 14, 2022

Compelling Zantrene Preclinical Kidney Cancer Data

March 9, 2022

Race Oncology: Application for quotation of securities - RAC

March 6, 2022

MD Anderson Preclinical AML Study on Zantrene Published

February 22, 2022

Race raises $29.7 million in oversubscribed SPP

December 20, 2021

Expanded Heart Protection Discovery for Zantrene

December 7, 2021

Race Oncology: Notification regarding unquoted securities - RAC

December 3, 2021

Race Oncology Investor Presentation - November 2021

November 23, 2021

Race Oncology Share Purchase Plan

November 23, 2021

AGM Presentations

November 22, 2021

Breakthrough Zantrene Heart Protection Discovery

November 21, 2021

University of Wollongong R&D Collaboration

November 8, 2021

Race secures sixth US patent for Zantrene

October 18, 2021

Race secures fifth US patent for Zantrene

October 5, 2021

Preclinical & Clinical Programs Update

September 30, 2021

Zantrene highly effective in Melanoma preclinical study

September 29, 2021

First Patient Dosed in Phase 1b/2 AML Trial

August 9, 2021

Race executes Israel AML Phase 2 Trial Contract

June 21, 2021

Race Executes Key Contract for Israel Phase 2 AML Trial

June 7, 2021

Contract to Commence Phase 2 Extramedullary AML Trial

June 1, 2021

Prospectus

May 5, 2021

Placement closes oversubscribed-Bonus Option Issue launched

May 4, 2021

Race investor briefing & updated presentation

May 4, 2021

Race Initiates Heart Safety Preclinical Study for Bisantrene

April 27, 2021

Second independent study shows Bisantrene inhibits FTO

April 15, 2021

Race Strategic Update March 2021

March 30, 2021

Race Initiates Extramedullary AML Preclinical Study

March 29, 2021

Race Initiates FTO Directed Kidney Cancer Preclinical Study

March 24, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 33 decks. Every deck is listed under its year.